Lv41
500 积分 2023-02-02 加入
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
5小时前
已完结
Prasinezumab: what have we learned from PASADENA and PADOVA?
22天前
已完结
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study
22天前
已完结
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
1个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
1个月前
已完结
Unlocking biological barriers: nonclinical safety considerations for RNA-based complex biologics
2个月前
已完结
Unlocking biological barriers: nonclinical safety considerations for RNA-based complex biologics
2个月前
已完结
In Vivo Imaging of Small Molecular Weight Peptides for Targeted Renal Drug Delivery: A Study in Normal and Polycystic Kidney Diseased Mice
3个月前
已完结
Simultaneous Detection of Adenosine-to-Inosine Editing and N6-Methyladenosine at Identical RNA Sites through Deamination-Assisted Reverse Transcription Stalling
3个月前
已完结
Exploring the Potentials of Antibody–siRNA Conjugates in Tumor Cell Gene Silencing without Cationic Assistance
3个月前
已完结
皖公网安备34019202002308
